Ardelyx executive sells 81,898 shares, exercises options
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an open-market sale of 81,898 shares of common stock at a weighted average price of $5.989 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported an open-market sale of 81,898 shares of common stock at a weighted average price of $5.989 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026, and the trades occurred in a price range from $5.97 to $6.0086. Following the sale, Williams directly holds 378,195 shares of Ardelyx common stock. On the same date, she also exercised a stock option to acquire 31,000 shares at an exercise price of $0.99 per share, reducing the outstanding option grant tied to those shares.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
3 txns
Insider
Williams Laura A
Role
Chief Patient Officer
Sold
81,898 shs ($490K)
Approx. gross sale proceeds
$490K
Approx. exercise cost
$31K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 31,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 31,000 | $0.99 | $31K |
| Sale | Common Stock | 81,898 | $5.989 | $490K |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,000 contracts (Direct);
Common Stock — 378,195 shares (Direct)
Footnotes (3)
- F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026.
- F2. Transaction was executed in multiple trades in prices ranging from $5.97 to $6.0086, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Key Figures
Shares sold: 81,898 shares
Sale price: $5.989 per share
Post-sale holdings: 378,195 shares
+3 more
6 metrics
Shares sold
81,898 shares
Open-market sale of Ardelyx common stock
Sale price
$5.989 per share
Weighted average sale price for the transaction
Post-sale holdings
378,195 shares
Direct Ardelyx common stock held after transactions
Options exercised
31,000 shares
Common shares acquired via stock option exercise
Option exercise price
$0.99 per share
Strike price of exercised stock option
Sale price range
$5.97–$6.0086 per share
Range of individual trade prices within the sale
Key Terms
Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average sale price financial
"The price reported ... reflects the weighted average sale price"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Ardelyx (ARDX) report for Laura A. Williams?
Laura A. Williams reported selling 81,898 Ardelyx shares. She executed an open-market sale of common stock at a weighted average price of $5.989 per share and remains a significant direct shareholder after the transaction.
At what prices did Laura A. Williams sell Ardelyx (ARDX) stock?
The reported weighted average sale price was $5.989 per share. Individual trades were executed in multiple transactions within a price range from $5.97 to $6.0086 per share, according to the disclosed footnote details.
Did Laura A. Williams exercise stock options in the latest Ardelyx (ARDX) Form 4?
Yes, she exercised options for 31,000 Ardelyx shares. The stock option carried an exercise price of $0.99 per share, converting derivative rights into additional common stock on the same date as the reported sale.
Was the Ardelyx (ARDX) insider sale by Laura A. Williams under a Rule 10b5-1 plan?
Yes, the sale was made under a Rule 10b5-1 trading plan. The plan was adopted on March 19, 2026, indicating the transactions were pre-arranged rather than newly decided at the time of execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
